Secondary Logo

Share this article on:

Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer

Cress, Rosemary D., DrPH; Chen, Yingjia S., MPH; Morris, Cyllene R., PhD; Petersen, Megan, MD; Leiserowitz, Gary S., MD

doi: 10.1097/AOG.0000000000000981
Original Research
Journal Club
Annual Awards

OBJECTIVE: To identify characteristics associated with long-term survival for patients with epithelial ovarian cancer using the California Cancer Registry.

METHODS: A descriptive analysis of survival of all California residents diagnosed with epithelial ovarian cancer between 1994 and 2001 was conducted using patients identified through the cancer registry with follow-up through 2011. Characteristics of the patients who survived more than 10 years (long-term survivors) were compared with three other cohorts: patients who survived less than 2 years, those who survived at least 2 but no more than 5 years, and those who survived at least 5 but no more than 10 years.

RESULTS: A total of 3,582 out of 11,541 (31%, confidence interval 30.2–31.8%) of the patients survived more than 10 years. Younger age, early stage, low-grade, and nonserous histology were significant predictors of long-term survival, but long-term survivors also included women with high-risk cancer.

CONCLUSION: Long-term survival is not unusual in patients with epithelial ovarian cancer, even in those with high-risk disease. Many of the prognostic factors are well known, but it remains to be determined why some patients with advanced-stage high-grade cancers survive longer than others with the same histology. These findings are important for patient counseling.

LEVEL OF EVIDENCE: III

Nearly one third of more than 11,000 patients diagnosed with epithelial ovarian cancer in California between 1994 and 2001 survived at least 10 years after diagnosis.

Department of Public Health Sciences, School of Medicine, University of California, Davis, Davis, and the Cancer Registry of Greater California, Public Health Institute, the California Cancer Reporting and Epidemiologic Surveillance (CalCARES) Program, Institute for Population Health Improvement, University of California Davis Health System, and the Division of Gynecologic Oncology, University of California Davis Medical Center, Sacramento, California.

Corresponding author: Rosemary D. Cress, DrPH, 1825 Bell Street, Suite 102, Sacramento, CA 95825; e-mail: rdcress@ucdavis.edu.

Supported by the National Cancer Institute Comprehensive Cancer Center Support Grant (P30CA93373).

Financial Disclosure The authors did not report any potential conflicts of interest.

Patients and physicians commonly perceive ovarian cancer as a highly fatal disease. Because most patients present with advanced-stage disease, the prognosis is often poor. Ovarian cancer 5-year survival varies significantly by stage but, for women diagnosed in 2004–2010, ranged from 92% for localized disease to 27% for distant.1

Although most women diagnosed with advanced-stage ovarian cancer will die of the disease, the biological behavior of ovarian cancer is quite variable. Even some of those patients with high-risk, advanced-stage ovarian cancer survive well beyond 5 years. With an increased focus on survivorship, understanding of this information becomes important for patient counseling. There is a paucity of data about long-term ovarian cancer survivors because very few clinical series or population-based database studies extend beyond 5 years of survival. The purpose of this study was to identify characteristics associated with long-term survival from epithelial ovarian cancer using the California Cancer Registry.

Back to Top | Article Outline

MATERIALS AND METHODS

This was a retrospective, cross-sectional descriptive analysis of patients diagnosed through the California Cancer Registry. This registry is the single largest population-based cancer registry in the United States and contains demographic, diagnostic, treatment, and outcome information extracted from medical records for every reportable cancer diagnosed among residents of the state since 1988. California law requires that physicians and hospitals report all cancer cases, and information is collected from diagnostic and treatment facilities. To ensure current follow-up for vital status and cause of death, the cancer registry database is linked annually to death certificates, hospital discharge data, Medicare files, the Department of Motor Vehicles, Social Security, and other administrative databases. Linkage to the National Death Index ensures capture of deaths occurring outside California as well as cause of death, and follow-up is higher than 96% for patients diagnosed since 2000. The California Cancer Registry is part of both the Centers for Disease Control and Prevention National Program of Cancer Registries and the National Cancer Institute Surveillance Epidemiology and End Results program and meets or exceeds the standards of both groups for data quality and completeness. This study was determined by the institutional review board at the University of California Davis to be exempt because only existing, deidentified data were included.

For this analysis we identified all patients residing in California and diagnosed with ovarian cancer between 1994 and 2001. We collected data on patient demographics (age, race–ethnicity, socioeconomic status, insurance status), year of diagnosis, cancer characteristics (stage at diagnosis, tumor grade, histology), and hospital. Patients were followed through December 31, 2011, thus allowing us at least 10 years of follow-up for all surviving patients. Characteristics of the patients who survived more than 10 years (long-term survivors) were compared with three other cohorts: patients who survived less than 2 years, those who survived at least 2 but no more than 5 years, and those who survived at least 5 but no more than 10 years. Only patients for whom ovarian cancer was the first or only cancer diagnosis were included. Patients diagnosed at autopsy were excluded from analysis.

Race–ethnicity in the cancer registry is based on information collected from medical records supplemented with linkage to algorithms to better identify Hispanics and Asian and Pacific Islanders. We categorized race–ethnicity as Hispanic, non-Hispanic white, non-Hispanic black, and non-Hispanic Asian–Pacific Islander. Neighborhood level socioeconomic status was based on U.S. Census characteristics linked to the address at diagnosis combined into the summary Yost index.2 To measure urban–rural differences, we used the census-based rural–urban commuting codes, which combine population density, urbanization, and commuting times, to categorize residence at diagnosis as urban, small town, or rural (http://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes.aspx). Insurance coverage was defined as private or government (including managed care and Medicare with supplement), Medicaid or low income, Medicare, insured not otherwise specified, and uninsured. Volume of treatment facilities was categorized according to how many patients with ovarian cancer received initial treatment at each facility during the study period.

Stage at diagnosis was defined based on a modification of American Joint Committee on Cancer staging system. Only invasive epithelial cancers were included. Tumors with International Classification of Diseases for Oncology, 3rd Revision morphology codes 8010–8570 (excluding 8240–8255) were considered epithelial tumors. Tumors were further categorized as serous (codes 8050, 8052, 8260, 8441, 8450, 8460, 8461), mucinous (codes 8471, 8481, 8480), clear cell (codes 8005, 8310, 8313), endometrioid (codes 8380, 8381, 8382), or adenocarcinoma not otherwise specified (codes, 8010, 8020, 8021, 8140, 8141, 8323, 8440, 8570). TNM staging was not included in the registry before 2004; thus, subset analysis could not be done on this factor. Early-stage patients may have included patients understaged because of inadequate surgical staging. The grading system included four grades with IV being classified as undifferentiated using the International Classification of Diseases for Oncology–World Health Organization system. Tumor grades were grouped into grades I and II compared with III and IV.

Patient demographic, hospital, and tumor characteristics were summarized using descriptive statistics. Associations between these factors and survival category were evaluated using χ2 tests. Multivariable logistic regression was done to estimate the odds of surviving more than 10 years while simultaneously controlling for demographic, clinical, and hospital characteristics. Statistical significance was defined by a P value <.05. Statistical computing was performed with SAS 6.12.

Back to Top | Article Outline

RESULTS

A total of 11,541 women residing in California were diagnosed with invasive epithelial ovarian cancer during the period of 1994–2001. Patient demographics, cancer characteristics, insurance status, and hospital volume are described in Table 1. Approximately one fourth of the patients were younger than 50 years of age. A majority of the patients were non-Hispanic whites, with smaller numbers of Hispanics, Asian and Pacific Islanders, and non-Hispanic blacks. Almost all patients resided in an urban area (97%). There were nearly twice as many cases categorized as grade III and IV as grade I and II, but grade information was missing in 27% of cases. Sixty-seven percent of ovarian cancers were stages III and IV, and only approximately 20% were stage I. Serous was the predominant histologic type followed by endometrioid, clear cell, and mucinous types. The majority of patients with ovarian cancer received their treatment at high-volume hospitals.

Table 1

Table 1

Patients were divided into four cohorts based on length of survival (Table 2). Most patients survived less than 5 years; however, 31.0% (confidence interval [CI] 30.2–31.8%) of all patients survived more than 10 years (long-term survivors). Nearly half of long-term survivors were 18–50 years old compared with 13% among those who survived less than 2 years. Hispanic and Asian and Pacific Islander patients made up a higher proportion of long-term survivors than other groups. A slightly higher proportion of patients who survived more than 10 years had private insurance. A higher percentage of patients who survived for at least 2 years resided in high socioeconomic status neighborhoods and a larger proportion were cared for in hospitals that treated more than 40 cases during the study period.

Table 2

Table 2

Although the majority of long-term survivors had stage I cancer, 32.4% (CI 30.9–33.9%) had stages III and IV disease at diagnosis. Tumor grade also varied significantly, with a predominance of low-grade cancers in the women surviving more than 10 years. If the patients with unknown grade are removed, approximately 58% of the long-term survivors had grades I and II cancers. Long-term survival favored those with endometrioid, clear cell, and mucinous types. However, 62.3% of stage I and II patients with grade 3 and 4 tumor survived 10+ years, and 66.2% of stage I and II patients with serous histology survived more than 10 years.

Odds ratios that favored survival greater than 10 years over shorter survival periods are shown in Table 3. Patients missing information on socioeconomic status, race–ethnicity, insurance, stage, grade, or cause of death were excluded from the multivariable analysis. Women with stage I cancer had very high odds of survival more than 10 years. Similar, but less marked, associations were detected for stages II and III compared with stage IV disease. Patients with low-grade tumors were more likely to be long-term survivors. The favorable prognoses persisted for mucinous, clear cell, and endometrioid histologies compared with serous after adjustment for other factors. Younger age also remained as a significantly positive prognostic factor. However, race, socioeconomic status, insurance, and hospital volume were no longer statistically significant. Results were similar when odds ratios were calculated separately for patients with stage I and II and those with stage III and IV (results not shown).

Table 3

Table 3

After patients with missing values were excluded from analysis, there were 954 patients with stages III and IV epithelial ovarian cancer (17.2% of a total of 5,536 patients) who survived more than 10 years (Table 4). Twenty-six percent of women younger than age 50 years survived more than 10 years, and although the majority of women older than age 75 years with late-stage ovarian cancer survived less than 2 years, 6% survived more than 10 years. A higher proportion of Hispanic and Asian and Pacific Islander patients survived more than 10 years. Although there were higher proportions of long-term survivors among patients with endometrioid tumors, 16% of patients with late-stage serous cancer survived more than 10 years.

Table 4

Table 4

Back to Top | Article Outline

DISCUSSION

This study provided a unique opportunity to examine the characteristics of women who are long-term survivors of epithelial ovarian cancer, commonly thought to be a highly fatal disease. There has been limited information about women surviving greater than 10 years, many of whom are cured. Using cancer registry data not only allowed us to collect long-term survival data beyond 10 years (most studies are limited to 5 years of survival3–5 3–5 3–5), but the cohort was far larger than seen in other studies.6 Most surprising was that nearly one third of patients with ovarian cancer were long-term survivors, which is very important for counseling about prognosis.

Tumor biology (cancer stage, grade, and histology) had the strongest associations with survival. Although long-term survival did vary based on race–ethnicity, socioeconomic status, and insurance status, none of these remained statistically significant after adjustments for the other covariates. As expected, patients with stage I cancers had the greatest likelihood of long-term survival, probably reflecting that many are actually cured of their disease.7,8 7,8 Chan identified four independent risk factors that were associated with survival in early-stage ovarian cancer: age, stage, tumor grade, and peritoneal cytology. Low-risk patients (none or one risk factor) had a 5-year survival of 88% compared with the high-risk group 75% (three or four risk factors), but all of these patients received adjuvant chemotherapy.7

Low-grade cancers had improved survival over high-grade cancers, consistent with earlier studies.5,9 5,9 Patients with grade 1 or 2 epithelial cancers were twice as likely to survive more than 10 years compared with those with grade 3 or 4 cancers in multivariate analysis. As noted, grade is often not independent of stage, because the majority of stage IA cancers are also grade 1. Grade also is not independent of histology in epithelial cancers, because several histologic types, including mucinous and endometrioid, are usually low grade, have a more indolent behavior, and are more likely to be confined to one ovary.10,11 10,11

Histology is also closely tied to both stage and grade, as noted previously.12 The histologies most commonly associated with long-term survival are endometrioid, clear cell, and mucinous, consistent with previous reports.5 It is not surprising that endometrioid and mucinous cancers should have a generally favorable prognosis, because they are typically also low grade and low stage.10–12 10–12 10–12 Clear cell cancers are a distinct entity that appears to have two different behaviors. Many clear cell cancers are early stage and often associated with endometriosis and therefore have a better prognosis than high-grade serous cancers.10,13 10,13 In contrast, advanced-stage clear cell cancers tend to have a poorer survival compared with high-grade serous cancers, probably as a result of relative chemotherapy resistance.10,13,14 10,13,14 10,13,14

One of the most surprising findings was that nearly one third of all long-term survivors had stages III and IV epithelial cancer, including serous cancers. The explanation for this is unclear, but there are several possibilities. Improved surgical techniques that result in a high percentage of patients with no or minimal residual disease have improved outcomes.15 The use of concomitant intraperitoneal and intravenous adjuvant chemotherapy has been associated with prolonged survival with a median overall survival of 110 months in patients debulked to no residual disease.16 Patients with advanced-stage ovarian cancer who are BRCA1 or BRCA2 mutation carriers have an improved survival compared with those without these mutations.17,18 17,18 It may be that there are somatic (as opposed to germline) genomic alterations that may account for long-term survival in patients with the same histology.19 Unfortunately, the cancer registry does not have information on the completeness of surgical debulking, use of intraperitoneal chemotherapy, BRCA mutation status, or genomic data, so these should be topics of future investigation.

Consistent with earlier studies,5,6,20–24 5,6,20–24 5,6,20–24 5,6,20–24 5,6,20–24 5,6,20–24 5,6,20–24 age had a great effect on overall survival in epithelial ovarian cancer and long-term survivors were more likely to be women younger than age 50 years. Young women are more likely to have low-stage and low-grade epithelial cancers,21 which points to a more favorable biological behavior; however, the better prognosis for younger women persisted after adjustment for stage, grade, and histology and was also seen in patients with advanced-stage disease, similar to prior studies.24,25 24,25 Better performance status may allow younger women to tolerate more aggressive surgery and chemotherapy.

Long-term survival may bring its own challenges beyond worry about recurrence. Studies have shown that patients with ovarian cancer are challenged with problems of anxiety, fatigue, sexual, social, and financial problems,26 which should be amenable to appropriate interventions. These studies highlight that physicians, especially those who provide primary care, should be prepared to address cancer survivorship needs in this group of patients.

Back to Top | Article Outline

REFERENCES

1. Howlander N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al.. SEER cancer statistics review, 1975–2011. Bethesda (MD): National Cancer Institute; 2014.
2. Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 2001;12:703–11.
3. Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, et al.. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 2006;108:521–8.
4. Chiang YC, Chen CA, Chiang CJ, Hsu TH, Lin MC, You SL, et al.. Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan. J Gynecol Oncol 2013;24:342–51.
5. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al.. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95(suppl 1):S161–92.
6. Yang KY, Kapp DS, Hu JM, Shin JY, Osann K, Chen LM, et al.. Long-term survivors of epithelial ovarian cancer: what can we learn from these women? 39th Annual Meeting Society of Gynecologic Oncologists. Philadelphia (PA): Elsevier; 2008. p. S135–6.
7. Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, et al.. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer 2008;112:2202–10.
8. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, et al.. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990;322:1021–7.
9. Chan JK, Munro EG, Cheung MK, Husain A, Teng NN, Berek JS, et al.. Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol 2007;109:12–9.
10. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 2011;43:420–32.
11. McMeekin DS, Burger RA, Manetta A, DiSaia P, Berman ML. Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis. Gynecol Oncol 1995;59:81–6.
12. Fleming ST, Kimmick GG, Sabatino SA, Cress RD, Wu XC, Trentham-Dietz A, et al.. Defining care provided for breast cancer based on medical record review or Medicare claims: information from the Centers for Disease Control and Prevention Patterns of Care Study. Ann Epidemiol 2012;22:807–13.
13. del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol 2012;126:481–90.
14. Ho CM, Huang YJ, Chen TC, Huang SH, Liu FS, Chang Chien CC, et al.. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol 2004;94:197–203.
15. Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. The Cochrane Database of Systematic Reviews 2011, Issue 8. Art. No.: CD007565. DOI: 10.1002/14651858.CD007565.pub2.
16. Landrum LM, Java J, Mathews CA, Lanneau GS Jr, Copeland LJ, Armstrong DK, et al.. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 2013;130:12–8.
17. Zhong Q, Peng HL, Zhao X, Zhang L, Hwang WT. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res 2015;21:211–20.
18. Sun C, Li N, Ding D, Weng D, Meng L, Chen G, et al.. The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis. PLoS One 2014;9:e95285.
19. Barlin JN, Jelinic P, Olvera N, Bogomolniy F, Bisogna M, Dao F, et al.. Validated gene targets associated with curatively treated advanced serous ovarian carcinoma. Gynecol Oncol 2013;128:512–7.
20. Akhtar-Danesh N, Elit L, Lytwyn A. Temporal trends in the relative survival among patients diagnosed with ovarian cancer in Canada 1992–2005: a population-based study. Gynecol Oncol 2011;123:192–5.
21. Chan JK, Urban R, Cheung MK, Osann K, Shin JY, Husain A, et al.. Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer 2006;95:1314–20.
22. O'Malley CD, Cress RD, Campleman SL, Leiserowitz GS. Survival of Californian women with epithelial ovarian cancer, 1994–1996: a population-based study. Gynecol Oncol 2003;91:608–15.
23. Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B. Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 2003;101:885–91.
24. Winter WE III, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al.. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:3621–7.
25. Chan JK, Loizzi V, Lin YG, Osann K, Brewster WR, DiSaia PJ. Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important? Obstet Gynecol 2003;102:156–61.
26. Wenzel LB, Donnelly JP, Fowler JM, Habbal R, Taylor TH, Aziz N, et al.. Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. Psychooncology 2002;11:142–53.
© 2015 by The American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.